Genesis Research Group is attending ISPOR Europe from 17-20 November and taking part in multiple thought leadership sessions, including an Issue Panel and HEOR Theater. You can find them at Booth 412.
Genesis Research Group warmly invites all industry professionals to join them at this November’s ISPOR Europe in Barcelona to explore its latest scientific posters and presentations, including a thought-provoking Issue Panel on strategic drug pricing, and an in-depth HEOR Theater on the value of planning with payer insights. Find out more below.
If you’re at the event, Genesis Research Group’s strategic, scientific, and BD teams will be available throughout, so book a meeting to ask them how Genesis’s agile, tech-enabled market access, HEOR, and real-world evidence partnerships can support your projects, or email solutions@genesisrg.com to request further information or copies of the slides.
ISSUE PANEL
Precision or Perception: Strategic Drug Pricing Anchored on Evidence
There is an urgency for life science companies to devise strategies that recognize the value of innovation supported by methodologies acceptable to payers. Pricing strategies must effectively address diverse challenges, including variations in assessment methodologies, payer archetypes, and regional affordability considerations.
The Genesis Research Group led Issue Panel from 10:15 – 11:15 on Monday 18 November will feature Adam Weston, MSc, and Priti Jhingran, PhD, of Genesis Research Group, Christopher Blanchette, PhD, MBA of Novo Nordisk, and Frank-Ulrich, PhD, of Technische Hochschule Nürnberg. It will provide an access and pricing researcher and methodologist perspective followed by an interactive debate with perspectives from both industry and payers.
HEOR THEATER
Planning With Payer Insights: Even the Best Economic Models Need Validation
This year’s Genesis Research Group HEOR Theater presentation explores the benefits of an integrated, cross-functional approach that incorporates payer insights upfront to validate the conceptualization of modeling framework in addition to input parameters. The session will demonstrate how this approach enhances the likelihood of success and maximizes value propositions for assets. Speakers from HEOR/economic modeling consultancy and life-sciences companies will share examples illustrating the effectiveness of validating economic models with payer insights.
Taking place at 11:45 – 12:15, Tuesday 19 November and moderated by Priti Jhingran, PhD, speakers include Dominic Jones-Phillips, PhD of Genesis Research Group, plus guests Smita Kothari, PhD, MBA, and Carole Longson, MBE.
ISPOR EUROPE POSTERS
Genesis Research Group posters at ISPOR Europe 2024
HTA75: Payer Perceptions of Health Inequalities in Reimbursement Decision Making: Results of a Global Survey. SA13: A Non-Systematic Review of Equity in Oncology HTA Submissions to NICE. HTA153: Health Equity Priorities for Pharmaceutical Manufacturers: Payer Perceptions from a Global Survey. SA27: Non-Systematic Review Evaluating Search Strategies Leveraged in HTA Submissions to NICE. RWD128: A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research Europe Conference. HTA264: Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey.
You can book at meeting with Genesis Research Group at ISPOR Europe here or email solutions@genesisrg.com.
